Safusidenib for IDH1-mutant glioma after main treatment
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 3 trial tests safusidenib, a targeted medicine, to help stop or slow the return of certain brain tumors with an IDH1 mutation. It focuses on people after initial treatment (surgery and/or radiation and temozolomide), aiming to improve outcomes during maintenance therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older when you sign consent.
- Your tumor must be IDH1-mutant (specifically R132H or R132C for Part 1, or other R132 variants for later parts) confirmed by lab testing.
- You must have a measurable tumor spot on brain MRI (large enough to measure) that fits “mainly enhancing” or “mainly non-enhancing” criteria.
- You can usually have had no more than 2 prior treatments for regrowth (and timing matters).
- If you’re in Parts 2–3, you also must have adequate blood/organ function and meet specific prior-treatment timing rules.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted therapy called safusidenib for people whose brain tumor (glioma) has an IDH1 mutation and who have already taken vorasidenib but the tumor kept growing. The study aims to see if safusidenib can help when vorasidenib stops working.
This trial tests an experimental pill called safusidenib for people with a slow-growing brain tumor (grade 2 glioma) that has an IDH1 mutation. The goal is to see if it can control the tumor and improve outcomes.
This trial tests a combination of two oral medications, olutasidenib and temozolomide, for people with a specific type of aggressive brain tumor (high-grade glioma) that has an IDH1 mutation. The goal is to see if this combination can help control the tumor after standard treatment like radiation.
This trial tests the drug vorasidenib for people with a slow-growing brain tumor (Grade 2 glioma) that has an IDH mutation. The goal is to see how well the drug works and how it affects your quality of life.
This Phase 2 study tests a combination of chemotherapy and radiation after surgery for certain brain tumors that are “IDH wildtype.” It aims to control the tumor and improve outcomes for people with specific types of glioma or glioblastoma.
This trial tests whether the drug vorasidenib, guided by a special PET scan, can help people with certain low-grade brain tumors that have come back or are still present after surgery. It aims to see if this approach is safe and effective.
Hear when a new Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.